Amarin CEO Mikhail resigns, Kostas named chair
Plus: BioCryst appoints Hutson chair and updates from Flare, Mytide and TScan
Amarin Corp. plc (NASDAQ:AMRN) is looking for a new president and CEO following the resignation of Karim Mikhail on March 27, a few weeks after activist investor Sarissa Capital Management defeated the company’s board in a proxy contest. Amarin said it disagreed with Mikhail’s assertion that he is entitled to severance payments. It also announced the appointment of Odysseas Kostas, senior managing director at Sarissa, as chair. Amarin markets cardiovascular drug Vascepa icosapent ethyl.
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) chose longtime board member Nancy Hutson to succeed Bob Ingram as chair. Hutson retired from Pfizer Inc. (NYSE:PFE) in 2006 and is on the boards of Clearside Biomedical Inc. (NASDAQ:CLSD), PhaseBio Pharmaceuticals Inc. (OTCQX:PHASQ) and Endo International plc. BioCryst is developing small molecules to treat rare diseases. ...